Please assess the completion status of the following clinical trial:

Trial Title: Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with stage 3 or 4 meibomian gland dysfunction~* moderate or marked symptoms of ocular discomfort, itching, or photophobia with limitations of activities~* moderate or severe meibomian gland dysfunction clinical signs~* mild to moderate conjunctival and peripheral corneal staining or increased conjunctival and corneal staining, including central staining~* increased signs of inflammation : moderate or severe conjunctival hyperemia, phlyctenulae~Exclusion Criteria:~* history of previous ocular or intraocular surgery~* evidence of acute or chronic infections or inflammation of the cornea and conjunctiva~* ocular allergy~* autoimmune disease~* history of intolerance or hypersensitivity to any component of the study medications~* use of topical ocular medications~* wearing contact lenses during the study period~* presence of current punctal occlusion~* pregnancy~* lactating women~* children

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline treatment group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).